Phorbol 12,13-dibutyrate and mitogens increase fructose 2,6-bisphosphate in lymphocytes. Comparison of lymphocyte and rat-liver 6-phosphofructo-2-kinase by Boscá, Lisardo et al.
Eur. J. Biochem. 175,317-323 (1988) 
0 FEBS 1988 
Phorbol 12J3-dibutyrate and mitogens 
increase fructose 2,6-bisphosphate in lymphocytes 
Comparison of lymphocyte and rat-liver 6-phosphofructo-2-kinase 
Lisardo BOSCA', Marina MOJENA', Ma. Jose M. DIAZ-GUERRA' and Carlos MARQUEZ3 
Instituto de Bioquimica, Facultad de Farmacia, Madrid 
Servicio de Endocrinologia Experimental, Clinica Puerta de Hierro, Madrid 
Servicio de Immunologia, Clinica Puerto de Hierro, Madrid 
(Received March 29, 1988) - EJB 880352 
The influence of tumour promoters and growth factors on glycolysis and on fructose-2,6-bisphosphate 
concentration was studied in isolated mouse spleen lymphocytes and in purified B-cells. The intracellular concen- 
tration of fructose 2,6-bisphosphate and the rate of lactate release were increased 2 - 3-fold in spleen lymphocytes 
exposed to active phorbol esters, mitogenic lectins, interleukin 4 or lipopolysaccharide. The maximal effect was 
observed after 1 h of exposure. In these cells hexose 6-phosphates increased 2-fold and 6-phosphofructo-2-kinase 
activity remained unchanged after treatment with phorbol 12,13-dibutyrate or with lectins. Exposure of B-cells 
to phorbol12,13-dibutyrate, interleukin 4 or lipopolysaccharide increased the glycolytic flux and the concentration 
of fructose 2,6-bisphosphate without relation to their mitogenic activity. 
Lymphocytes and rat liver 6-phosphofructo-2-kinase were partially purified using the same procedure. The 
lymphocyte enzyme was not inhibited by sn-glycerol3-phosphate in contrast to the potent inhibition observed in 
liver. Treatment of both enzymes with the catalytic subunit of the cyclic-AMP-dependent protein kinase failed to 
inactivate 6-phosphofructo-2-kinase from lymphocytes. These differences suggest that lymphocytes and liver 
contain different forms of this enzyme. 
The interaction of isolated lymphocytes with specific 
mitogens elicits different biochemical and morphological 
changes including receptor mobilization [l], changes in ionic 
fluxes [2], translocation of the phospholipid/Ca' +-dependent 
protein kinase [3] and expression of c-myc and c--0s genes [4]. 
One of the early biochemical events observed after exposure of 
these cells to mitogens such as concanavalin A was an 
important increase in the glycolytic flux causing the release of 
large amounts of lactate to the incubation medium. Glucose 
and glutamine seem to be the main energetic fuels for resting 
and activated lymphocytes IS]. 
Fru(2,6)P2, the most potent stimulator of PFK-1, is in- 
volved in the control of glycolysis and gluconeogenesis in liver 
and other tissues [6, 71. In the case of PFK-1 partially purified 
from human B-lymphocytes and B-chronic lymphocytic 
leukemia cells, a different sensitivity to Fru(2,6)P2 has been 
found [8]. In recent years it has been reported [9, 101 that 
Fru(2,6)P2 increases after exposure of quiescent chicken em- 
bryo fibroblasts to the tumour promoter phorboll2-myristate 
13-acetate, mitogenic concentration of insulin or transfor- 
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2, 6-phosphofructo-2-kinase (EC 2.7.1.105); C-kinase, phospholipid/ 
Ca2+-dependent protein kinase (EC 2.7.1.37). 
mation by the Rous sarcoma virus. This increase in Fru(2,6)P2 
can be related to the increased glycolytic flux observed under 
these conditions. 
The aim of the present work is to determined whether 
Fru(2,6)P2 concentration can be altered after exposure of 
lymphocytes to tumour promoters or mitogens and to study 
the influence of changes in the concentration of this metabolite 
on the glycolytic flux. It was therefore decided to use active 
phorbol esters that directly activate the C-kinase [3, 111, 
mitogenic lectins specific for T-cells, and the specific B-cell 
growth factor, interleukin 4 [12-141 and the murine B-cell- 
specific mitogen, lipopolysaccharide [15, 161. 
The kinetic properties of lymphocyte PFK-2 were com- 
pared with those of liver, suggesting the presence in lympho- 
cytes of an isoenzymatic form different from liver. 
MATERIALS AND METHODS 
Materials 
[3H]Thymidine (24 Ci/mmol) and [Y-~~PIATP (3000 Ci/ 
mmol) were from Amersham International (Amersham, UK). 
DEAE-cellulose (DE52) and glass-fiber filters (GF/C) were 
from Whatman. Blue Sepharose and Sephadex G-25 (me- 
dium) were from Pharmacia (Uppsala, Sweden). Hexose phos- 
phates, sn-glycerol 3-phosphate and nucleotides were from 
Boehringer (Mannheim, FRG). Growth medium RPMI 1640 
and other biochemicals were from Sigma (St Louis, MO, 
USA). Chemicals were purchased from Merck (Darmstadt, 
FRG). Triton X-100 was from Packard (Downers Grove, 
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USA). Sterile filters were obtained from Millipore (Bedford, 
USA). Lipopolysaccharide (LPS, Escherichia coli strain 
055:B5W) was from Difco (Detroit, USA) and IL-4 activity 
was from supernatant from COS cell line transfected with the 
IL-4 gene kindly provided by Dr R. Palacios (Base1 Institut 
for Immunology, Switzerland). 
Cell prepuration 
Lymphocytes were prepared from BALB/c mice spleens, 
aged 3 -4 months. After centrifugation in a Ficoll-Isopaque 
discontinuous gradient (600 x g for 20 min) [17], the mononu- 
clear leucocyte layer was washed and centrifuged (350 x g 
for 5 min) twice in Hepes-buffered medium lacking calcium 
(150 mM NaCI, 4 mM Na2HP04, 0.6 mM MgS04, 0.5 mM 
CaCI2, 6 mM glucose, 50 pM 2-mercaptoethanol, 15 mM 
Hepes pH 7.2). Lymphocytes were counted and resuspended 
at 5 x lo6 cells/ml in Hepes-buffered medium for short-term 
incubations (less than 5 h). For long-term incubations lym- 
phocytes were prepared under sterile conditions and incubat- 
ed at 37°C at 5 x lo6 cells/ml in plastic petri dishes (Costar, 
6 mm diameter) in 3 ml RPMI 1640 medium (Sigma) buffered 
with 20 mM Hepes pH 7.2 and supplemented with 50 pM 2- 
mercaptoethanol, 60 pg/ml penicilin, 100 pg/ml streptomicin 
and 5% foetal calf serum. B-cells were obtained after depletion 
of T lymphocytes by incubating for 40 min the lymphocyte 
preparation with a monoclonal anti-Thy 1 antibody followed 
by treatment with rabbit complement and maintained at 
5 x 106 ceIls/ml. 
Cell incubation 
For short-term incubations 5 - 8 ml lymphocyte or B-cell 
suspensions were placed on sterile plastic flasks (20 in1 ca- 
pacity) and incubated at 37°C for 15 min in a shaking water- 
bath (30 cycles/min) previous to the addition of the growth 
factors or other ligands. At appropriate times samples were 
collected, and the cells were pelleted (800 x g for 30 s) and 
used for the determination of enzyme activities and metabolite 
concentrations. 
For long-term incubations the additions were performed 
at the beginning of the incubation period. The ligand solutions 
were sterilised by passing through a 0.22-pm pore-size filter. 
Measurement of metabolites 
To measure Fru(2,6)Pz, aliquots of 0.3 ml lymphocyte 
incubations were centrifuged (800 x g for 30 s) and the pellets 
heated with 0.5 ml hot 50 mM NaOH at 80°C for 10 min. 
Fru(2,6)P2 was assayed in these alkaline extracts [IS]. For the 
measurement of hexose 6-phosphate, 3-ml cell suspensions 
were centrifuged (800 x g  for 30 s) and the pellets were 
homogenized in 1 ml ice-cold 0.5 M perchloric acid. After 
centrifugation (5000 x g for 5 min) the supernatants were 
neutralized with saturated KzC03 and used to measure Glc6P 
and Fru6P enzymically [9]. Lactate release was measured in 
the incubation medium treated with 1 vol. 1 M perchloric acid 
~91. 
Purification of PFK-I 
PFK-1 activity was partially purified from isolated lym- 
phocytes. Cells (2 x lo8) were homogenized at 4°C in 3 ml of 
100 mM KC1, 5 mM MgC12, 1 mM dithioerythritol, 5 mM 
potassium phosphate and 20mM Hepes pH 7.4. After 
centrifugation at 100000 x g for 30 min, the supernatant was 
fractionated with poly(ethy1ene glycol) 6000 and the 5 - 15% 
pellet was resuspended in 3 ml homogenization buffer sup- 
plemented with 30% (by vol.) glycerol. After passing through 
a column of ATP-agarose (0.5 x 3 cm) equilibrated with resus- 
pension buffer, PFK-1 activity was eluted with 0.5 mM 
MgATP, 0.1 mM Fru6P. Fractions containing activity were 
pooled and stored at -20°C. The enzyme activity was mea- 
sured spectrophotometrically in a reaction mixture that 
contained 100 mM KC1,5 mM MgC12, 3 mM MgATP, 1 mM 
potassium phosphate, 0.05 mM AMP, 20 mM Hepes pH 7.2 
and the indicated concentrations of Fru(2,6)P2. After a 5-min 
incubation at 37"C, the reaction was started by the addition 
of various concentrations of Fru6P. 
Purification of PFK-2 from lymphocytes and rut liver 
PFK-2 was partially purified from isolated lymphocytes 
(2 x lo8 cells) and from liver of rat fed ad libitum. Both purifi- 
cations were run in parallel essentially as previously described 
[19,20]. Cells or liver were homogenized at 4°C in the presence 
of 4ml ice-cold 100 mM KC1, 2 mM EDTA, 1 mM 
dithioerythritol, 20 mM potassium phosphate pH 7.4. After 
centrifugation at 100000 x g  for 30 min, the supernatant was 
fractionated with poly(ethy1ene glycol) 6000 and the corre- 
sponding 3 - 15% pellet was resuspended in 2 ml of a medium 
containing 20% glycerol (by vol.), 100mM KCI, 5mM 
MgClZ, 1 mM dithioerythritol and 20mM Hepes pH 7.2 
(buffer A). Both fractions were applied to columns of blue 
Sepharose (0.5 x 4 cm) equilibrated with buffer A. The 
columns were washed with buffer A and buffer A supplement- 
ed with 0.4M KCI until the protein concentration in the 
eluates was negligible. PFK-2 was eluted (at 8 - 12 mM pot- 
assium phosphate) with a gradient of 0 - 25 mM potassium 
phosphate (pH 7.2). Fractions containing activity were pooled 
and stored at -30°C. 
Measurement of PFK-2 activity 
For the measurement of PFK-2 activity, cell extracts were 
prepared from lymphocyte pellets ( 5  - 10 x lo6 cells) as pre- 
viously indicated for the purification of the enzyme until the 
fractionation with poly(ethylene glycol). The 3 - 15% pellet 
was resuspended in buffer A lacking glycerol. PFK-2 was 
assayed in this buffer at 30°C in the presence of 2 mM 
MgATP, 2 mM Fru6P and 6 mM Glc6P in a final volume of 
300 pl. Aliquots were taken at 0, 2, 5 and 10 min and were 
immediately treated with 1 vol. 100 mM NaOH at 80°C for 
10 min. The amount of Fru(2,6)Pz formed was measured as 
previously described. The reaction was linear during the time 
observed. 
The sensitivity to inhibition by sn-glycerol 3-phosphate 
[20] was measured in blue Sepharose-purified PFK-2 from 
lymphocytes and liver. The assay was carried out at 30'C in 
the presence of buffer A lacking glycerol, and supplemented 
with 0.5 niM MgATP, 0.1 mM Fru6P and various concen- 
trations of sn-glycerol 3-phosphate. The amount of 
Fru(2,6)Pz formed was measured as previously described. 
Incubation of PFK-2 with the catalytic subunit 
of CAMP-dependent protein kinase and C-kinase 
Partially purified PFK-2 from lymphocytes or from liver 
(50 pU) was incubated at 30°C with catalytic subunit (1.5 pg) 
in a final volume of 0.2 ml containing buffer A without 
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Fig. 1 ,  Effect ofphorboll2,13-dihutyrate (PDBu) on Fru(2,6jP2 concentration and on lactate release in isolated lymphocytes. Spleen lymphocytes 
were isolated and incubated at 5 x lo6 cells/ml in Hepes-buffered medium. (A) Fru(2,6)P2 (0 )  and lactate release (0) after a 4-h incubation. 
(B) Time course for the increase in Fru(2,6)P2 concentration in lymphocytes incubated in the absence ( A )  or in the presence (A) of 100 ng/ 
ml phorbol dibutyrate. Results are means f SEM for three separate experiments (A), or the means of two epxperiments (B) 
glycerol. The reaction was started by the addition of 0.5 mM 
MgATP. After 10 min the reaction was stopped by the ad- 
dition of 5 mM EDTA. Samples (40 pl) were assayed for PFK- 
2 activity at pH 6.6 (active form) and at pH 8.5 (total activity) 
in the presence of 100 mM KCl, 1 mM dithiothreitol, 2 mM 
MgATP, 1 mM potassium phosphate and 1 mM Fru6P. The 
buffers used were 50 mM Pipes pH 6.6 or 50 mM Tris/HCl 
pH 8.5 [21]. 
C-kinase activity was purified from rat brain by DEAE- 
cellulose (DE52) and protamine-agarose chromatography, 
and the activity was followed by its histone kinase activity as 
previously described [22]. The enzyme had a specific activity of 
0.73 U/mg protein when assayed with histone H1 as substrate. 
PFK-2 from lymphocytes was also incubated with 10 pU C- 
kinase at 30°C and in a medium containing 20 pg/ml 
leupeptin, 100 mM KCl, 5 mM dithiothreitol, 0.5 mM 
MgATP and 20 mM Hepes pH 7.2, in the presence or absence 
of 0.5 M CaC12, 10 pg/ml phosphatidylserine and 0.5 pg/ml 
oleoylacetyl glycerol. Aliquots were taken after a 5-min incu- 
bation and PFK-2 was assayed for the affinity of Fru6P at 
different pH values. 
Thymidine incorporation 
Thymidine incorporation was measured in lymphocytes 
cultured for a period of 25 h. The culture was pulsed by adding 
1 lCi/mol of 13H]thymidine to the growth medium. After a 
5-h incubation, the medium was aspirated and the cells were 
collected by centrifugation (800 x g for 30 s) and lysed in 9 ml 
ice-cold 0.1% SDS, 0.5% Triton X-100. After absorbing in 
GF/C filters, the filters were washed three times, oven-dried 
and counted in 2 ml scintillation medium. 
RESULTS 
Ejyect ofphorbol12,13-dibutyrate andmitogens on Fru(2,6)Pz 
Initial experiments were carried out in spleen lymphocytes. 
As shown in Fig. lA ,  when these cells were exposed to 
phorbol 12,13-dibutyrate in Hepes-buffered medium, a time- 
and dose-dependent increase was observed both in the intra- 
cellular concentration of Fru(2,6)Pz and in the rate of lactate 
release. The half-maximal effect of phorbol dibutyrate was 
obtained at a dose of 30 ng/ml. This dose was in the range of 
the values to obtain the half-maximal of both translocation 
of the C-kinase in lymphocytes [3] and the increase in the 
concentration of Fru(2,6)P2 in fibroblasts [9]. The time course 
of the effect of phorbol dibutyrate at 100 ng/ml of Fru(2,6)Pz 
concentration is shown in Fig. 1 B. To elicit the half-maximal 
increase in concentration 30 min was required, and about 1 h 
for stability, reaching a value of 18 pmol/mg protein. Similar 
results were obtained with 12-0-tetradecanoyl phorbol 13- 
acetate. 
Phorbol esters act through the activation of the C-kinase 
as a substitute for the requirements of diacylglycerol, without 
affecting the intracellular concentration of calcium [16]. Cal- 
cium mobilization together with C-kinase translocation 
stimulated lymphocyte growth [23, 241. To study the effect 
of an increase in the cytosolic concentration of calcium on 
Fru(2,6)P2, isolated lymphocytes were exposed for 45 inin 
to the calcium ionophore A23187. As shown in Fig. 2, at 
concentrations lower than 0.5 pM of this ionophore, the 
Fru(2,6)Pz concentration and the rate of lactate release were 
increased. However, higher concentrations of ionophore and 
longer periods of exposure decreased the cellular viability as 
determined by the release of lactate dehydrogenase activity to 
the incubation medium. The exposure of lymphocytes to both 
phorbol dibutyrate (50 ng/ml) and the calcium ionophore 
(0.5 pM) did not produce any synergistic effect on the concen- 
tration of this metabolite. 
The effect of mitogenic lectins such as ConA on lympho- 
cytes was also studied. When total spleen lymphocytes were 
exposed to ConA, a concentration-dependent increase was 
observed both in the rate of lactate release and in the concen- 
tration of Fru(2,6)P2 (Fig. 3) .  Both parameters exhibited the 
half-maximal effect at the same concentration of ConA (0.3 - 
0.4 pg/ml). Moreover, the half-maximal mitogenic activity,of 
ConA determined by the incorporation of [3H]thymidine in 
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Fig. 2. Effect of A23187 on Fru(2,6)P2 concentration (a) and on 
lactate release ( 0 )  in isolated lymphocytes. Cells were incubated for 
45 min with different concentrations of a freshly prepared solution of 
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Fig. 3. Effect of ConA on Fru(2,6)P2 concentration and on lactate 
release in isolated lymphocytes. Spleen lymphocytes ( 5  x lo6 cells/ml) 
were incubated for 3 h in Hepes-buffered medium. (A), Fru(2,6)P2 
concentration; ( A )  tactate release. Results are means f SEM of three 
separate experiments 
the macromolecular fraction over a period of incubation of 
30 h was 0.30 pg/ml. This is in agreement with the observed 
effects on glycolysis, suggesting a correlation between acti- 
vation of glvcolvsis and growth. Phvtohemamzlutinin. another 
mitogenic lectin for lymphocytes, induced the same pattern 
of changes in Fru(2,6)Pz and on lactate release. The half- 
maximal effect was obtained at 1 pg/ml. 
In liver and other cells a decrease has been described in 
Fru(2,6)P2 concentration concomitant with an increase in 
the intracellular concentration of cyclic AMP [6, 251. When 
lymphocytes were incubated with the permeable chloro- 
phenylthio derivative of cyclic AMP no changes were ob- 
served in the concentration of Fru(2,6)P2 nor in the rate of 
lactate release. However, a dose-dependent decrease in the 
concentration of Fru(2,6)P2 was found when isolated 
hepatocytes were incubated with this analogue in the range of 
concentrations used for the incubation of lymphocytes (data 
not shown). 
Fructose 2,6-bisphosphate in B-cells 
Since spleen cell populations are a mixture of B and T 
lymphocytes, the results previously reported may be the conse- 
quence of activation involving one of these different types of 
cells. For this reason B-cells were purified and stimulated 
either with their specific cell growth factor (IL-4) or with a 
polyclonal B-cell mitogen in order to obtain cell-type-specific 
responses. When B-cells were incubated with phorbol 
dibutyrate, an increase was observed, time- and dose-depen- 
dent, in Fru(2,6)Pz concentration and in lactate release (data 
not shown). This phenomenon was essentially similar to that 
observed in spleen lymphocytes. To establish the involvement 
of C-kinase activation on the acceleration of glycolysis and 
in the rise in the concentration of Fru(2,6)P2, B-cells were 
incubated for three time periods (30 min, 4 h or 30 h) in the 
presence of either phorbol dibutyrate, B-cell growth factor 
(IL-4) or LPS. As summarized in Table 1, when B-cells were 
exposed to these ligands Fru(2,6)Pz concentration was in- 
creased to different extent in all cases although without re- 
lation to their mitogenic capacity as estimated by the ability 
to incorporate [3H]thymidine. Combination of phorbol 
dibutyrate with the mitogen LPS failed to act synergistically 
on Fru(2,6)Pz, suggesting a common way to increase its con- 
centration. 
The inactive a-phorbol 12,13-didecanoate failed to pro- 
voke changes in the rate of lactate release and Fru(2,6)Pz 
concentration. These results suggest that activation of C- 
kinase in an early event that activates glycolysis in B-cells. 
PFK-I, PFK-2 and hexose phosphates concentrations 
The above-reported results suggest a correlation between 
lactate production and Fru(2,6)P2 concentration in lympho- 
cytes and in B-cells. The increase in the concentration of the 
bisphosphate may be a consequence either of an increase in 
the activity of PFK-2, or in the concentration of its substrates, 
or both. As shown in Table 2 no significant changes in PFK- 
2 activity were found, whether the enzyme was assayed at 
saturating (5  mM) or subsaturating (100 pM) concentrations 
of Fru6P. No changes in PFK-1 activity were observed under 
these conditions (data not shown). However, the concen- 
tration of the hexose phosphates increased after exposure of 
lymphocytes to 1 pg/ml of ConA (2.5-fold increase), 50 pg/ml 
phorbol dibutyrate (2-fold increase) and to a lesser extent 
when LPS was used (1.5-fold). The increase in the concen- 
tration of hexose phosphates was parallel to the changes in 
Fru(2,6)P2 concentration. Moreover, these changes persisted 
for at least 4 h. This was in agreement with previous reports 
[26, 271. The rise in the concentration of Fru(2,6)Pz can be 
explained, at least in part, by the changes in Fru6P concen- 
tration. To explain the rise in the glycolytic flux, it was decided 
to investigate the influence on PFK-1 activity of the changes 
in Fru6P and Fru(2,6)P2, substrate and effector, respectively, 
of this enzyme. Fig. 4 shows the relative effects of both hexoses 
on the activity of this enzyme, purified from lymphocytes by 
ATP-agarose affinity chromatography. 
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Table 1. Fru(2,6)-Pz concentration, lactate release and [3H]thymidine incorporation in isolated B-cells 
Lymphocytes (5 x lo6 cells/ml) were exposed to phorbol 12,13-dibutyrate (PDBu), a-phorbol 12,13-didecanoate (a-PDD), I t - 4  (l%, by vol., 
of supernatant containing IL-4 activity) and LPS. B-cells were incubated in Hepes-buffered medium, and with RPMI 1640 medium for 
thymidine incorporation. Values are means SEM for at least three separate experiments. [jHIThymidine uptake is given as mean of two 
separate experiments. n. d., not determined 
Addition Fru(2,6)Pz after Lactate after [jH]- 
4 h  Thymidine 
10 min 20 min 30 min 4 h  after 30 h 
pmol/mg protein pmol/mg dpm/mg 
protein protein 
None 1 1 f l  1 0 k 1  1 0 k 1  9 f 3  0.41 f 0.09 5,100 
PDBu, 50 ng/ml 1 0 k 1  10*2 25 5 3 28 f 4 0.67 & 0.1 1 5,600 
a-PDD, 100 ng/ml 9 i l  1 4 k 2  10*2 8 k 3  0.40 i 0.10 5,300 
IL-4, 1% 1 1 + 2  2 1 k 3  1 6 k 2  1 7 f 2  0.54 f 0.10 8,700 
LPS, 50 pg/ml 1 6 k 1  23 f 2 23 2 26 f 3 0.94 f 0.14 40,000 
LPS + PDBu, 50 pg/ml + 50 ng/ml n. d. n. d. 31 5 4  30 & 4 0.93 f 0.17 n.d. 
Table 2. Fru(2,6)P2 and hexose-phosphate concentratians and PFK-2 
activity in lymphocytes 
Spleen lymphocytes were incubated for 4 h in the presence of appro- 
priate additions in Hepes-buffered medium. At the end of the incu- 
bation time, cells were centrifuged (800 x g for 30 s) and the pellets 
processed as described. Hexose 6-phosphates were measured from 
perchloric acid extracts. PFK-2 activity was assayed at  pH 7.2 in the 
presence of 2 mM MgATP, 2 mM Fru6P, 6 mM Glc6P; or 0.1 mM 
Fru6P, 0.3 mM Glc6P 
Addition Fru(2,6)Pz Glc6P PFK-2 with Fru6P at 
+ Fru6P 
2 mM 0.1 mM 
pmol/mg nmol/mg pU/mg 
protein protein protein 
None 8 * 2  3.2 f 0.3 5.3 f 0.2 3.0 f 0.1 
PDBu, 50 ng/ml 18 k 3 6.8 f 0.4 5.9 f 0.3 3.2 f 0.2 
ConA, 1 pg/ml 21 & 2 8.2 f 0.6 5.7 f 0.3 3.3 0.2 
LPS,50pg/ml 1 6 + 3  4.8f0.3 5.7k0.4 3.4k0.2 
Characterization of lymphocyte PFK-2 
To characterize the nature of the PFK-2 present in mouse 
spleen lymphocytes, the enzyme was partially purified by blue- 
Sepharose affinity chromatography. Rat liver PFK-2, whose 
more relevant kinetic properties are known in detail [28, 291, 
was also purified in parallel with the lymphocyte enzyme in 
order to compare the physical and kinetic properties of both 
activities. The behaviour of both enzymes on fractionation by 
poly(ethy1ene glycol) and on the retention and elution in the 
blue-Sepharose column were similar. The comparison of the 
kinetic properties between both preparations showed 
important differences in some parameters. Both enzymes ex- 
hibited hyperbolic kinetics for the affinity for MgATP ( K ,  
0.1 M) and for Fru6P (K,  80 and 50 pM for lymphocyte 
and liver respectively) when assayed in the presence of 1 mM 
potassium phosphate (Fig. 5 A). However, the enzymes were 
different in the response to sn-glycerol3-phosphate. Whereas 
lymphocyte PFK-2 activity remained unchanged when as- 
sayed in the presence of concentrations up to 1 mM of this 
metabolite, the liver enzyme exhibited the reported inhibition 
[30] with an apparent Ki value of about 100 pM (Fig. 5B). 
The lack of inhibition by sn-glycerol 3-phosphate has been 
previously reported for the purified bovine heart enzyme [20]. 
One of the most relevant properties of rat liver PFK-2 is to 
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Fig. 4. Stimulation of PFK-1 activity by Fru(2,6)P2. The enzyme was 
partially purified from lymphocytes by ATP-agarose affinity 
chromatography as described in Materials and Methods. The assay 
was performed at 37°C and pH 7.2 with 0.8 pg/ml enzyme in the 
presence of 3 mM MgATP, 0.2 mM AMP, 1 mM potassium phos- 
phate and various concentrations of Fru(2,6)PZ. The reaction was 
started by the addition of Fru6P 
exhibit kinetic changes when the enzyme is phosphorylated 
by the cyclic-AMP-dependent protein kinase. These changes 
in the maximal activity of the enzyme are observed at acidic 
pH (6.6), whereas at pH 8.5 the kinetic differences between the 
phosphorylated and dephosphorylated enzyme are minimized 
[21]. When the effect of treatment with the catalytic subunit 
of the cyclic-AMP-dependent protein kinase was studied, it 
was observed that the lymphocyte enzyme failed to show 
kinetic changes, while under the same conditions the purified 
liver enzyme exhibited the reported inhibition at pH 6.6. These 
results are shown in Table 3. The absence of response to cyclic- 
AMP-dependent protein kinase is in agreement with the lack 
of changes observed in Fru(2,6)P2 concentration and in lac- 
tate release in isolated lymphocytes incubated with a per- 
meable cyclic AMP derivative. 
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Fig. 5.  Affinityfor Fru(2,6)P2 and inhibition by sn-glycerol3-phosphate of PFK-2 from mouse spleen lymphocyte and rat liver. The enzyme was 
purified by blue-Sepharose affinity chromatography. (A) Affinity for Fru6P. The enzymes were assayed at pH 7.2 in the presence of 2 mM 
MgATP and 1 mM potassium phosphate. (B) Inhibition by sn-glycerol 3-phosphate. The enzymic activity was measured at pH 7.2 in the 
presence of 0.5 mM MgATP and 0.1 mM Fru6P. The activities in the absence of sn-glycerol 3-phosphate were 6 and 22 mU/mg protein for 
the lymphocyte and liver cnzyme respectively. (0) Lymphocytes preparation; ( 0 )  liver enzyme 
Table 3. Effect of treatment with the catalytic subunit of the cyclic- 
A MP-dependent protein kinase on purifed PFK-2 from mouse spleen 
lymphocytes and rat liver 
PFK-2 was purified by blue-Sepharose affinity chromatography. 
After incubation with the catalytic subunit for 10 min in the presence 
of 0.5 mM MgATP, PFK-2 activity was assayed at pH 6.6 and at 
pH 8.5 in the presence of 1 mM Fru6P and 2 mM MgATP. The values 
shown are means k SEM for three separate experiments 
PFK-2 Addition PFK-2 activity at 
catalytic 1 mM pH 6.6 pH 8.5 
subunit MgATP 
mU/mg protein 
Lymphocyte - - 8.8 f 0.9 8.4 + 0.7 + - 9.1 f 1.0 8.7 f 1.0 + + 9.3 1.1 8.5 f 0.9 
Liver - - 24 k 3  33 f 4  + - 20 + 3  34 f 3  + + 8 f 1  32 f 3  
To ascertain whether the affinity of lymphocyte PFK-2 
for Fru6P may be affected by C-kinase activity, partially 
purified enzyme (blue-Sepharose chromatography) was incu- 
bated with C-kinase purified from rat brain in the presence 
or absence of Ca2+ and phospholipids. PFK-2 activity was 
then assayed both at saturating (1 and 0.5 mM) and subsatu- 
rating (50 and 100 pM) concentrations of Fru6P and at pH 
6.6, 7.2 and 8.6. Under these conditions no changes were 
observed in the enzyme activity, in agreement with the results 
obtained after exposure of lymphocytes to phorbol dibutyrate 
(Table 2) .  
DISCUSSION 
The data presented in this study show that in total mouse 
spleen lymphocytes and in B-cells both the rate of lactate 
release and Fru(2,6)P2 concentration were increased when 
cells were exposed either to phorbol esters, to a calcium 
ionophore or activated by specific lymphocyte mitogens such 
as lectins or LPS. The mechanism by which these different 
ligands act increasing the glycolytic flux may be related, at 
least in part, to an increase in the concentration of Fru6P and 
Fru(2,6)P2, the substrate and effector, respectively, of PFK- 
1. In fact, at concentrations of substrates [ATP and Fru6PI 
and effectors [AMP, phosphate and Fru(2,6)P2] similar to 
those prevailing in resting lymphocytes, this enzyme is very 
sensitive to simultaneous changes in Fru6P and Fru(2,6)P2 
concentrations. Consistent with these findings is the obser- 
vation that the half-maximal effects on lactate release and 
on Fru(2,6)P2 were obtained with the same doses either of 
phorbol dibutyrate, calcium ionophore or lectins. 
The observed rise in Fru6P may be the consequence of the 
increased glucose uptake after exposure of lymphocytes to 
different growth factors [31, 321. This increase, in turn, may 
be related to the rise in Fru(2,6)P2 as expected for the relative 
values of the K ,  of PFK-2 for Fru6P (80 pM) and the changes 
in substrate concentration (from 70 to 250 pM). 
One of the most rapid changes induced after exposure of 
lymphocytes to active phorbol esters is the translocation of 
the C-kinase activity from cytosol to membranes, although 
activation of C-kinase is sufficient to increase Fru(2,6)P2 and 
glycolysis either in spleen lymphocytes or in B-cells. These 
changes cannot be attributed to stable modifications in the 
kinetic properties of PFK-2 activity (i. e. phosphorylation by 
C-kinase). Accordingly, the increase in Fru(2,6)P2 after ex- 
posure of lymphocytes to phorbol esters requires more than 
30 min to reach stability. The changes in hexose phosphate 
323 
concentration may account for the observed acceleration of 
glycolysis. 
The effect of phorbols on lymphocyte growth is quite 
different: T-cells are induced to proliferate after exposure to 
phorbols and to calcium ionophore [24] whereas B-cells do 
not undergo proliferation under these conditions [33]. ConA 
and phytohemoglutinin, mitogens for T-cells, increased 
phosphoinositol lipid turnover resulting in translocation of 
C-kinase activity and in mobilization of intracellular calcium 
[34- 361. Consistent with the translocation of C-kinase is the 
accumulation of Fru(2,6)P2 and the enhancement of glycoly- 
sis observed after exposure of lymphocytes to these lectins. 
One of the proliferative signals elicited by the polyclonal 
mitogen of B-cell LPS is the translocation of C-kinase from 
cytosol to membranes and, as would be expected, the pattern 
of glycolytic changes resembled those obtained after exposure 
of lymphocytes to phorbol dibutyrate. When B-cell growth 
factor (IL-4) was used, glycolysis and Fru(2,6)P2 were also 
moderately increased (60%) despite the fact that this growth 
factor was unable to decrease C-kinase activity from cytosol. 
In accordance with this, it has been shown that LPS and IL-4 
bypass early mitogenic signals, such as phosphoinositol lipid 
degradation and calcium mobilization through an unknown 
mechanism [16, 371. 
Lymphocyte PFK-2 was characterized and compared with 
the rat liver enzyme. Both enzymes were completely absorbed 
on a blue-Sepharose column ad were eluted under analogous 
conditions, suggesting a similarity between the proteins. In 
the presence of phosphate as effector, both enzymes, exhibited 
roughly the same affinity for Fru6P. However, the purified 
lymphocyte enzyme failed to be inhibited by treatment with 
the catalytic subunit of the cyclic-AMP-dependent protein 
kinase. Moreover, the enzyme does not respond to the inhibi- 
tory action of sn-glycerol 3-phosphate. Taken together, these 
results suggest important differences in the activity of both 
enzymes. The properties of lymphocyte PFK-2 are very simi- 
lar to those described for the beef heart and foetal hepatocyte 
isoenzymes [20, 381. 
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